Brand Name(s): Calcimar; Miacalcin
CAS nº: 47931-85-1
(kal si toe nin)
About Calcitonin
This new site is dedicated exclusively to calcitonin.
It provides you with the most extensive product information and up-to-date resources regarding this medication, including related news articles, medical studies, an image library and all the necessary information on dosage and side effects.
Whether you are an average consumer or a pharma industry professional, you can now find out everything you need to know about calcitonin on this reference site, as well as take part in our open discussion forum by sharing your own knowledge and experience with people who are using this medication.
This unique site will also provide you with inside industry news on which companies or organizations are playing an important part in its research, development, production and promotion. It is your one-stop site for a total calcitonin experience!
Why is this medication prescribed?
Calcitonin is a hormone used to treat symptoms of Paget's disease of the bone, hypercalcemia (high levels of calcium in the blood) and postmenopausal osteoporosis (bone weakening). This medicine is often ordered for cancer patients experiencing bone pain due to metastasis.
This medication reduces the breakdown of bone. It causes less bone tissue to be reabsorbed, and slows the rate of bone destruction and decreases the amount of calcium released into the blood.
It is sold under the brand name Calcimar® in the United States.
Latest News
Bone Medical further positive results from oral osteoporosis drug trial
Bone Medical Limited (ASX:BNE) has obtained important positive data on blood levels of peptide from...
[more]Correlation of Procalcitonin and Cytokine Expression with Dehiscence of Wartime Extremity Wounds
Background: Despite technological advances in the treatment of severe extremity trauma, the timing...
[more]Unigene to Present at the 20th Annual Roth Capital Partners Growth Stock Conference
Unigene Laboratories, Inc.’s President and CEO, Dr. Warren Levy, will speak at the ROTH Capital...
[more]Unigene Initiates Phase I/II Clinical Study for Oral Calcitonin
Unigene Laboratories, Inc. (OTCBB: UGNE) has initiated a Phase I/II clinical study in the U.S. with...
[more]Bone Medical Positive New Data From Oral Osteoporosis Drug Trial
Bone Medical Limited has been advised of new positive data from its second clinical trial conducted...
[more]